Key Developments: Aastrom Biosciences Inc (ASTM.O)

ASTM.O on Consolidated Issue listed on NASDAQ Capital Market

2.66USD
23 Sep 2014
Price Change (% chg)

$0.04 (+1.38%)
Prev Close
$2.62
Open
$2.64
Day's High
$2.66
Day's Low
$2.55
Volume
76,050
Avg. Vol
209,917
52-wk High
$7.00
52-wk Low
$2.55

Search Stocks

Latest Key Developments (Source: Significant Developments)

Aastrom Biosciences Inc announces closing of public offering of common stock and full exercise of underwriters' option to purchase additional shares
Wednesday, 17 Sep 2014 08:30am EDT 

Aastrom Biosciences Inc:Closing of its underwritten public offering of 15,784,313 shares of its common stock at a price to the public of $2.55 per share, including 2,058,823 shares sold pursuant to the full exercise of the underwriters' option to purchase additional shares.Gross proceeds of about $40.3 mln.Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. acted as sole book-running manager for the offering.  Full Article

Aastrom Biosciences announces pricing of public offering of common stock
Thursday, 11 Sep 2014 08:30am EDT 

Aastrom Biosciences Inc:Prices public offering of 13,725,490 shares of its common stock at a price to the public of $2.55 per share.Aastrom has also granted the underwriters a 30-day option to purchase up to an additional 2,058,823 shares of common stock.Offering is expected to close on or about Sept. 16 subject to customary closing conditions.Ladenburg Thalmann & Co. Inc., subsidiary of Ladenburg Thalmann Financial Services Inc. is acting as sole book-running manager for offering.Gross proceeds to Aastrom from this offering are expected to be about $35,000,000 before deducting underwriting discounts and commissions and other estimated offering expenses.All of shares in offering are to be sold by Company.  Full Article

Aastrom Biosciences Inc appoints Chief Financial Officer
Wednesday, 4 Jun 2014 08:45am EDT 

Aastrom Biosciences Inc:Appoints Gerard Michel as Chief Financial Officer and Vice President, Corporate Development of the company.  Full Article

Aastrom Biosciences Inc completes acquisition of Sanofi's Cell Therapy and Regenerative Medicine Business
Monday, 2 Jun 2014 08:45am EDT 

Aastrom Biosciences Inc:Completes acquisition of Sanofi's cell therapy and regenerative medicine (CTRM) business unit.As announced on April 21 Aastrom paid $4 mln in cash and $2.5 million in a promissory note to acquire the CTRM business, which includes three marketed products in the United States and Europe as well as manufacturing and production centers in the U.S. and Denmark.  Full Article

Aastrom Biosciences Inc to acquire Sanofi's Cell Therapy and Regenerative Medicine Business
Monday, 21 Apr 2014 08:31am EDT 

Aastrom Biosciences Inc:Agreement to acquire Sanofi's Cell Therapy and Regenerative Medicine (CTRM) business.Purchase price of $6.5 mln, with $4 mln payable in cash at closing and $2.5 mln payable in form of a promissory note.  Full Article

Aastrom Biosciences Inc enters into $15 mln equity commitment with Lincoln Park Capital
Monday, 27 Jan 2014 04:05pm EST 

Aastrom Biosciences Inc:Says it has entered into a stock purchase agreement with Lincoln Park Capital Fund, LLC, an institutional investor.Says under the terms of the agreement, it has the right to sell up to $15 million in shares of common stock to Lincoln Park over a thirty-month period subject to certain limitations and conditions set forth in the purchase agreement.  Full Article

Aastrom Biosciences Inc Announces Appointment Of Chief Financial Officer - Form 8-K
Monday, 26 Aug 2013 05:06pm EDT 

Aastrom Biosciences Inc reported in its Form 8-K that the Company has appointed Michael Elliston its Treasurer, Secretary and Principal Finance and Accounting Officer, effective immediately. Mr. Elliston will continue to serve as the Company‚Äôs Controller, a position he has held with the Company since December 2011.  Full Article

Aastrom Biosciences Inc Announces Closing Of Public Offering Of Common Stock And Warrants
Friday, 16 Aug 2013 11:27am EDT 

Aastrom Biosciences Inc announced the closing of the previously announced underwritten public offering of 29,000,000 shares of its common stock, and warrants to purchase up to an aggregate of 29,000,000 shares of common stock, at a price to the public of $0.30 per share. The warrants have a per share exercise price of $0.375, are exercisable immediately, and expire five years from the date of issuance. Aastrom has also granted the underwriters a 45-day option to purchase additional shares of common stock and warrants to cover over-allotments, if any. As of the closing date, the underwriters have purchased an additional 1,000,000 shares of common stock and 1,000,000 warrants to purchase an aggregate of 1,000,000 shares of common stock to cover over-allotments. The gross proceeds to Aastrom from this offering, including the over-allotment, were $9,000,000 before deducting underwriting discounts and commissions and other estimated offering expenses. All of the shares in the offering were sold by the Company. The Company intends to use the net proceeds from the offering to conduct its clinical development programs including the Phase 2b ixCELL-DCM clinical trial, working capital needs, and for other general corporate purposes. Aegis Capital Corp. acted as sole book-running manager for the offering. Maxim Group LLC acted as a co-manager for the offering.  Full Article

Aastrom Biosciences Inc Announces Pricing Of Public Offering Of Common Stock and Warrants
Tuesday, 13 Aug 2013 09:59am EDT 

Aastrom Biosciences, Inc. announced that it has priced a public offering of 29,000,000 shares of its common stock, and warrants to purchase up to an aggregate of 29,000,000 shares of common stock, at a price to the public of $0.30 per share. The warrants have a per share exercise price of $0.37, are exercisable immediately, and expire five years from the date of issuance. The gross proceeds to Aastrom from this offering are expected to be approximately $8,700,000 before deducting underwriting discounts and commissions and other estimated offering expenses. All of the shares in the offering are to be sold by the Company. The Company intends to use the net proceeds from the offering to conduct its clinical development programs including the Phase 2b ixCELL-DCM clinical trial, working capital needs, and for other general corporate purposes.  Full Article

Aastrom Biosciences Inc Announces Strategic Change In Research And Development Programs; Executes Corporate Restructuring
Wednesday, 27 Mar 2013 08:45am EDT 

Aastrom Biosciences Inc announced strategic change in research and development programs to focus on the clinical development of lead product, ixmyelocel-T, for the treatment of dilated cardiomyopathy (DCM). Aastrom, which recently initiated the Phase 2b ixCELL-DCM clinical trial, previously received a U.S. orphan drug designation for the use of ixmyelocel-T in the treatment of DCM. As a result of the strategic change, Aastrom will stop enrollment and end the Phase 3 REVIVE clinical trial in patients with critical limb ischemia (CLI). In addition, the Company is executing a corporate restructuring that will reduce staff and operating expenses by approximately 50%. The ixCELL-DCM trial is a randomized, double-blind, placebo-controlled Phase 2b study. Approximately 108 patients will be enrolled at about 30 sites in the U.S. In the study, ixmyelocel-T is administered via catheter-based injections to patients with advanced heart failure due to ischemic DCM. The primary endpoint of the trial is the average number of events per patient, which include all-cause mortality, all-cause hospitalizations or unplanned hospital visits to treat worsening heart failure. Patients will be followed for a total of 12 months.  Full Article

Search Stocks